29 results were returned
Almost two years ago, the Higher Regional Court Düsseldorf first iterated new liability criteria with respect to Second Medical Use Patents (cf. decision Östrogenblocker of May 5, 2017, docket no. I-2 W 6/17).
The Supreme Court has confirmed that a patent for a dosage regime of a drug used to treat erectile dysfunction (ED) was obvious over the prior art.
The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...
In Australia the application of the Patent Term Extension provisions of the Patents Act 1990 have been construed narrowly so that PTEs are applicable to only certain types of pharmaceutical patents.
Much has been written about the implications of the July 2017 Supreme Court decision in Actavis v Eli Lilly in which Lord Neuberger delivered the judgment of the Court.
In a much-awaited decision handed down on 22 May 2017, the US Supreme Court in TC Heartland v Kraft Foods held that the "patent venue statute" (28 USC §1400(b)) should be construed narrowly.
The United Kingdom Supreme Court (UKSC) today handed down its judgment in the case of Actavis UK Limited and others v Eli Lilly and Company ( UKSC 46) that has significantly changed the law of patent infringement ...
Overall, the new DRR and AMMDP provide further clarity to the provisions of the new DAL. The obvious step toward improving the review and approval process, and the reduction in the need for onsite review for many ...
In a judgment handed down today the UK Supreme Court has upheld the appeal of Kymab who had challenged Regeneron's patents covering Kymab's 'Kymouse' transgenic mouse.
The Patents Court has rejected a public interest defence and granted an injunction, following a finding that patents for a medical device were valid and infringed.